These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening. Hu X; Legler PM; Southall N; Maloney DJ; Simeonov A; Jadhav A J Comput Aided Mol Des; 2014 Jul; 28(7):765-78. PubMed ID: 24958623 [TBL] [Abstract][Full Text] [Related]
3. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography. Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088 [TBL] [Abstract][Full Text] [Related]
5. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Zuniga JE; Schmidt JJ; Fenn T; Burnett JC; Araç D; Gussio R; Stafford RG; Badie SS; Bavari S; Brunger AT Structure; 2008 Oct; 16(10):1588-97. PubMed ID: 18940613 [TBL] [Abstract][Full Text] [Related]
6. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. Ho M; Goh CH; Brothers MC; Wang S; Young RL; Ou Y; Lui JN; Kalafatis M; Lan X; Wolf AE; Rienstra CM; Wilson BA Protein Sci; 2012 Mar; 21(3):318-26. PubMed ID: 22170566 [TBL] [Abstract][Full Text] [Related]
7. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Pires-Alves M; Ho M; Aberle KK; Janda KD; Wilson BA Toxicon; 2009 Mar; 53(4):392-9. PubMed ID: 19168088 [TBL] [Abstract][Full Text] [Related]
8. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Li B; Cardinale SC; Butler MM; Pai R; Nuss JE; Peet NP; Bavari S; Bowlin TL Bioorg Med Chem; 2011 Dec; 19(24):7338-48. PubMed ID: 22082667 [TBL] [Abstract][Full Text] [Related]
9. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Jin R; Sikorra S; Stegmann CM; Pich A; Binz T; Brunger AT Biochemistry; 2007 Sep; 46(37):10685-93. PubMed ID: 17718519 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5. Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023 [TBL] [Abstract][Full Text] [Related]
11. Benzoquinones as inhibitors of botulinum neurotoxin serotype A. Bremer PT; Hixon MS; Janda KD Bioorg Med Chem; 2014 Aug; 22(15):3971-81. PubMed ID: 24984937 [TBL] [Abstract][Full Text] [Related]
12. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA. Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327 [TBL] [Abstract][Full Text] [Related]
13. Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A. Bremer PT; Pellett S; Carolan JP; Tepp WH; Eubanks LM; Allen KN; Johnson EA; Janda KD J Am Chem Soc; 2017 May; 139(21):7264-7272. PubMed ID: 28475321 [TBL] [Abstract][Full Text] [Related]
14. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme. Ambrin G; Kumar R; Singh BR Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744 [TBL] [Abstract][Full Text] [Related]
15. Substrate binding mode and its implication on drug design for botulinum neurotoxin A. Kumaran D; Rawat R; Ahmed SA; Swaminathan S PLoS Pathog; 2008 Sep; 4(9):e1000165. PubMed ID: 18818739 [TBL] [Abstract][Full Text] [Related]
16. Examination of α-exosite inhibitors against Botulinum neurotoxin A protease through structure-activity relationship studies of chicoric acid. Xue S; Seki H; Remes M; Šilhár P; Janda K Bioorg Med Chem Lett; 2017 Nov; 27(22):4956-4959. PubMed ID: 29050781 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds. Minnow YV; Goldberg R; Tummalapalli SR; Rotella DP; Goodey NM Arch Biochem Biophys; 2017 Mar; 618():15-22. PubMed ID: 28137423 [TBL] [Abstract][Full Text] [Related]
18. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin. Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764 [TBL] [Abstract][Full Text] [Related]
19. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A. Dickerson TJ; Smith GR; Pelletier JC; Reitz AB Curr Top Med Chem; 2014; 14(18):2094-102. PubMed ID: 25335884 [TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design. Patel KB; Kononova O; Cai S; Barsegov V; Parmar VS; Kumar R; Singh BR Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129933. PubMed ID: 34023445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]